Oxymethylene aryl compounds and uses thereof

A compound, aryl technology, applied in the field of oxymethylene aryl compound and its use, can solve the problems of elevated, undiscovered PDE cell type selectivity, etc.

Inactive Publication Date: 2011-04-20
CYMABAY THERAPEUTICS
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The second component is the failure to respond to a hyperglycemic challenge to increase insulin release above an already elevated basal output
Inhibitors of cAMP phosphodiesterases have been shown to increase insulin secretion in vitro and in vivo, including PDE1C, PDE3B, PDE10 (Han P et al., J Biol Chem. 6 Aug 1999; 274(32):22337-44; Harndahl L et al., J Biol Chem. 2002 Oct 4; 277(40):37446-55; WalzHA et al People, J Endocrinol. 2006 Jun;189(3):629-41; Choi YH et al., J Clin Invest. 2006 Dec;116(12) : 3240-51; and Cantin LD et al., Bioorg Med Chem Lett. 2007 May 15; 17(10): 2869-73), but so far, PDEs not found to have the cell-type selectivity necessary to avoid undesired effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxymethylene aryl compounds and uses thereof
  • Oxymethylene aryl compounds and uses thereof
  • Oxymethylene aryl compounds and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0367] 4-[4-(4-Methanesulfonyl-phenoxymethyl)-thiazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester

[0368]

[0369]4-(4-Chloromethyl-thiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester (intermediate 1,463 mg, 1.46 mmol), 4-methanesulfonyl-phenol (252 mg, 1.46 mmol) and K 2 CO 3 (404 mg, 2.92 mmol) in acetone (25 mL) overnight. After cooling, the solid was filtered through a pad of celite. The filtrate was concentrated in vacuo. The residue was purified on silica gel (EtOAc-hexanes, 1:1) to give the desired product. 1 H NMR (CDCl 3 ): δ7.88 (2H, d, J = 8.8Hz), 7.23 (1H, s), 7.12 (2H, d, J = 8.8Hz), 5.24 (2H, s), 4.21 (2H, br), 3.17 (1H, m), 3.04 (3H, s), 2.88 (2H, m), 2.11 (2H, m), 1.73 (2H, m), 1.47 (9H, s).

example 2

[0372] 4-[4-(4-Imidazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester

[0373]

[0374] 1 H NMR (DMSO-d 6 ): δ8.12(1H, s), 7.63(2H, m), 7.54(2H, d, J=9.2Hz), 7.15(2H, d, J=9.2Hz), 7.05(1H, s), 5.15 (2H, s), 3.98 (2H, m), 3.21 (1H, m), 2.87 (2H, m), 2.01 (2H, m), 1.52 (2H, m), 1.39 (9H, s).

example 3

[0376] 4-[4-(4-Acetylamino-phenoxymethyl)-thiazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester

[0377]

[0378] 1 H NMR (DMSO-d 6 ): δ9.77(1H, s), 7.57(1H, s), 7.45(2H, d, J=9.0Hz), 6.94(2H, d, J=9.0Hz), 5.04(2H, s), 3.98 (2H, m), 3.18 (1H, m), 2.82 (2H, m), 2.02 (2H, m), 1.99 (3H, s), 1.51 (2H, m), 1.39 (9H, s).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Use of oxymethylene aryl GPR119 agonists and DPP IV inhibitors for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control are provided.

Description

Background technique [0001] Diabetes can be divided into two clinical syndromes: type I diabetes and type II diabetes. Type I diabetes or insulin-dependent diabetes mellitus is a chronic autoimmune disease characterized by insulin-producing beta-cells (hereinafter referred to as "islet cells" or "islet cells") in the islets of Langerhans of the pancreas. ) are lost in large numbers. As these cells are progressively destroyed, the amount of insulin secreted decreases, eventually leading to hyperglycemia (abnormally high levels of glucose in the blood) when the amount secreted falls below that required for euglycemia (normal levels of blood sugar). content). Although the exact trigger of this immune response is unknown, type 1 diabetics have high levels of antibodies directed against pancreatic β-cells (hereinafter referred to as "β-cells"). However, not all patients with high levels of these antibodies develop type 1 diabetes. [0002] Type II diabetes, or non-insulin depen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/401A61K31/4523A61K31/4985A61K31/506
CPCA61K31/4985A61K31/401A61K45/06A61K31/506A61K31/4523A61P3/06A61P3/08A61P3/10A61K31/38A61K2300/00
Inventor 玛丽亚·E·威尔逊杰弗里·约翰逊L·爱德华·克莱门茨赵祖春陈新
Owner CYMABAY THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap